## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report that AcrIIC5(Nch), a homologue of the anti-CRISPR protein AcrIIC5(Smu), inhibits Nme1Cas9 by preventing target DNA binding. They state that AcrIIC5(Nch) targets the PAM-interacting domain (PID), that strong binding requires guide RNA pre-loaded on Cas9, that a crystal structure of AcrIIC5(Nch) was determined, that critical residues were identified, and that docking predicts occupation of the Cas9 DNA binding pocket, suggesting a mechanism similar to AcrIIA2 and AcrIIA4.
- **Visible evidence base** Abstract text only; no experimental details, structural statistics, docking parameters, or quantitative data are provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, crystallographic data and refinement statistics, docking methodology and scores, mutagenesis data, binding affinity measurements, and any control experiments

## Reviewer
- **Overall assessment** The abstract presents a plausible mechanistic hypothesis for AcrIIC5(Nch) inhibition of Nme1Cas9, consistent with prior work on AcrIIC5(Smu). However, the evidence base available for this review is limited to the abstract, and several key claims cannot be evaluated without the full manuscript. The central mechanistic conclusion, that AcrIIC5(Nch) occupies the DNA binding pocket, is supported only by a docking prediction, which is not experimentally validated in the abstract. The claim that guide RNA pre-loading is required for strong binding is new and potentially important, but no quantitative binding data are visible. Overall, the work appears to be a solid contribution to the anti-CRISPR field, but the case for the proposed mechanism is not fully established from the supplied material.
- **Who would be interested in the results, and why** Researchers studying CRISPR-Cas biology, anti-CRISPR proteins, and bacterial immunity would be interested. The work also has relevance for those developing CRISPR-Cas9 tools, particularly type II-C systems, and for understanding how anti-CRISPRs can be engineered or countered. The structural and mechanistic insights may appeal to structural biologists and protein engineers.
- **Major strengths** The abstract clearly states a focused mechanistic question and builds on prior work with AcrIIC5(Smu). The finding that guide RNA pre-loading is required for strong inhibition is a novel and testable claim. The use of X-ray crystallography to determine the structure of AcrIIC5(Nch) is a significant technical achievement. The proposed mechanism, occupation of the DNA binding pocket, is consistent with known anti-CRISPR strategies and provides a clear framework for further study.
- **Major Concerns**  
  - **Concern ID** R1-M1  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Evidence sufficiency  
    **Claim pointer** The authors claim that AcrIIC5(Nch) inhibits Nme1Cas9 by occupying the Cas9 DNA binding pocket, based on a protein docking algorithm.  
    **Evidence pointer** Abstract, docking statement; location not provided  
    **Concern** The central mechanistic conclusion is based solely on a computational docking prediction. No experimental validation, such as mutagenesis of the predicted interface, co-crystallization, or binding competition assays, is described in the abstract.  
    **Why it matters** Docking predictions are hypothesis-generating, not confirmatory. Without experimental support, the claim that AcrIIC5(Nch) occupies the DNA binding pocket remains speculative, and the proposed similarity to AcrIIA2 and AcrIIA4 is not established.  
    **Resolution test** Provide experimental evidence, such as alanine-scanning mutagenesis of predicted interface residues, hydrogen-deuterium exchange, or a co-crystal structure of AcrIIC5(Nch) with Nme1Cas9, that directly demonstrates occupation of the DNA binding pocket.  
  - **Concern ID** R1-M2  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Evidence sufficiency  
    **Claim pointer** The authors claim that strong binding of AcrIIC5(Nch) to Nme1Cas9 requires guide RNA pre-loaded on Cas9.  
    **Evidence pointer** Abstract, binding statement; location not provided  
    **Concern** No quantitative binding data, such as dissociation constants or kinetic parameters, are provided in the abstract. The claim is stated without visible experimental support.  
    **Why it matters** This is a novel claim that distinguishes AcrIIC5(Nch) from other anti-CRISPRs. Without quantitative evidence, the reader cannot assess the strength of the effect or whether it is specific to guide RNA loading versus other conformational states.  
    **Resolution test** Provide binding affinity measurements (e.g., surface plasmon resonance, isothermal titration calorimetry, or fluorescence polarization) for AcrIIC5(Nch) binding to Nme1Cas9 with and without guide RNA, including appropriate controls.  
  - **Concern ID** R1-M3  
    **Severity** Major  
    **Blocking** No  
    **Axis** Technical completeness  
    **Claim pointer** The authors state that they identified amino acid residues critical for AcrIIC5(Nch) function.  
    **Evidence pointer** Abstract, mutagenesis statement; location not provided  
    **Concern** The abstract does not specify which residues were identified, how they were selected, or what functional assays were used to test them.  
    **Why it matters** Without this information, the significance of the mutagenesis data cannot be evaluated, and the link between specific residues and the proposed mechanism is unclear.  
    **Resolution test** In the full manuscript, clearly list the critical residues, describe the rationale for their selection, and present functional data (e.g., inhibition assays, binding assays) for each mutant.
- **Minor Comments**  
  - **Concern ID** R1-m1  
    **Severity** Minor  
    **Axis** Clarity  
    **Affected element** Abstract, mechanism statement  
    **Evidence pointer** Abstract, docking statement; location not provided  
    **Issue** The phrase "likely occupies" is appropriately cautious, but the abstract does not explain why the docking result is considered reliable or how the algorithm was validated.  
    **Required correction** Add a brief statement in the abstract or full text describing the docking method and any validation steps, such as comparison with known structures or cross-validation.  
  - **Concern ID** R1-m2  
    **Severity** Minor  
    **Axis** Completeness  
    **Affected element** Abstract, structural data  
    **Evidence pointer** Abstract, crystallography statement; location not provided  
    **Issue** The abstract mentions a crystal structure of AcrIIC5(Nch) but does not state the resolution or whether the structure is of the free protein or a complex.  
    **Required correction** Include the resolution and the biological context of the structure (e.g., apo or bound state) in the abstract or full text.  
  - **Concern ID** R1-m3  
    **Severity** Minor  
    **Axis** Context  
    **Affected element** Abstract, comparison to AcrIIA2 and AcrIIA4  
    **Evidence pointer** Abstract, mechanism statement; location not provided  
    **Issue** The comparison to AcrIIA2 and AcrIIA4 is made without describing the structural or functional basis for the similarity.  
    **Required correction** Briefly state the specific evidence (e.g., structural alignment, binding site overlap) that supports the comparison.
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are blocking because the central mechanistic claim and the novel binding requirement are not supported by experimental evidence in the abstract. R1-M3 is non-blocking but requires clarification in the full manuscript.
- **Assessment against Nature-style criteria**  
  - **Originality** The work appears original in its focus on AcrIIC5(Nch) and the novel finding of guide RNA-dependent binding. However, the proposed mechanism is similar to previously described anti-CRISPRs, so the originality is incremental rather than paradigm-shifting.  
  - **Scientific importance** The work is of interest to the anti-CRISPR and CRISPR biology communities, but the abstract does not demonstrate broad significance beyond these fields.  
  - **Interdisciplinary readership** The topic is specialized and likely to appeal mainly to molecular biologists, structural biologists, and microbiologists. The abstract is not written to attract a broader readership.  
  - **Technical soundness** The technical approach is appropriate, but the abstract does not provide enough detail to assess the rigor of the crystallography, docking, or binding experiments.  
  - **Readability for nonspecialists** The abstract is concise and generally clear, but terms such as "PAM-interacting domain" and "guide RNA pre-loaded" may require background knowledge. The abstract does not provide sufficient context for nonspecialists to appreciate the significance of the findings.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents a plausible hypothesis, but the central claims require experimental validation that is not visible in the supplied material. If the full manuscript provides the missing binding data and experimental support for the docking prediction, the work could be considered supportive.

## Risk / unsupported claims
- The claim that AcrIIC5(Nch) occupies the Cas9 DNA binding pocket is unsupported by experimental evidence in the abstract and relies solely on a docking prediction.
- The claim that guide RNA pre-loading is required for strong binding is unsupported by quantitative data in the abstract.
- The identification of critical residues is mentioned but not described, making the claim unverifiable from the abstract.
- The comparison to AcrIIA2 and AcrIIA4 is stated without supporting structural or functional evidence in the abstract.